not recommend genetic testing of a cardiac arrest survivor when the cardiac arrest remains unexplained, despite comprehensive clinical testing. The document highlights the high costs involved and difficulties interpreting VUS as the reasons for this recommendation.
Next-generation sequencing has reduced the costs of genetic testing, and broad panels with large numbers of genes are now widely available. A recent report on postmortem genetic testing in unexplained sudden cardiac death using broad-panel genetic testing reported pathogenic variants in 27% of victims. 5 However, little literature exists on the use of such broad panels in unexplained cardiac arrest survivors, where the yield may be expected to be higher than in sudden unexplained death. Therefore, the clinical utility of broad panel genetic testing in cardiac arrest survivors remains unclear.
We analyzed a large registry of unexplained cardiac arrest survivors in whom genetic testing had been undertaken to identify the yield of pathogenic variants and look for predictors of a positive finding. In particular, we aimed to compare phenotype-guided and phenotype-negative testing in terms of identifying pathogenic variants and VUS. We hypothesized that genetic testing in phenotype-negative cases would have a lower but yet significant yield when compared with those with a clinical phenotype.
Methods

Patient Enrollment
Details of the CASPER (Cardiac Arrest Survivors with Preserved Ejection fraction Registry) have previously been reported. 2 Briefly, CASPER is a national registry that examines phenotype-genotype correlation and assesses test performance in familial sudden death and unexplained cardiac arrest. Cardiac arrest survivors were eligible for enrollment if they had experienced an unexplained cardiac arrest with documented ventricular tachycardia or ventricular fibrillation requiring direct current cardioversion or defibrillation, and subsequent testing demonstrated normal left ventricular function (left ventricular ejection fraction ≥50%) and normal coronary arteries (no coronary stenosis >50%). Patients with known causes for cardiac arrest, including an ECG diagnostic of long QT syndrome (LQTS; persistent resting QTc >460 ms for males and 480 ms for females 6 ) or Brugada syndrome, 7 hypertrophic cardiomyopathy, marked hypokalemia, drug overdose, or commotio-cordis, were excluded. Furthermore, patients with recognized forms of idiopathic ventricular tachycardia were also excluded. In addition, enrollment in this study required undertaking of genetic testing. Cases where there was a missing or incomplete genetic report were excluded. The protocol was approved by the Health Sciences Research Ethics Board of the University of British Columbia and at each enrolling center, and all patients included in this study have given informed consent (Registry of Unexplained Cardiac Arrest).
Clinical Testing
Patients received standard testing to determine the cause of the cardiac arrest, including a resting 12-lead ECG, echocardiography, and assessment of coronary anatomy by selective angiography, or computed tomography. Patients who met the enrollment criteria underwent further testing, including high-lead ECG, 8 signal-averaged ECG, exercise stress testing, ambulatory monitoring, cardiac magnetic resonance imaging, and procainamide and epinephrine provocation tests. Investigators had discretion to perform testing as guided by the clinical presentation and results of previous testing. Exercise stress tests were performed using a Bruce or modified Bruce protocol. ECGs were recorded before, during, and ≤6 minutes after exercise. Procainamide and epinephrine infusions were performed using standard techniques.
9,10 right ventricular (RV) angiography and RV biopsy was performed in selected cases where arrhythmogenic RV cardiomyopathy was suspected. In the majority of cases, family cardiac evaluation did not inform the original assessment of phenotype in the proband. This may have been able to guide genetics testing in some cases. Furthermore, because of the limited availability of data on family members, we were not able to use cosegregation of variants to inform the diagnosis of the proband.
Genetic Testing
Genetic testing was performed at the discretion of the investigating physician in keeping with contemporary guidelines and availability. Testing before 2007 was restricted to limited research testing. Thereafter, clinical testing was performed through local hospital or commercial laboratories using either direct Sanger sequencing or, more recently, next-generation sequencing techniques (with variants confirmed using Sanger sequencing). Genetic tests undertaken were grouped for analysis as single gene; single phenotype; limited multiphenotype where <20 genes in total were tested for ≥1 clinical phenotype; and broad multiphenotype, where large panels of arrhythmia or cardiomyopathy genes were tested. Pathogenic variants and VUS were initially identified from laboratory reports (Figure 1 ). Features of each variant were analyzed and assigned a level of evidence for pathogenicity as very strong; strong; moderate; or supporting (see Data Supplement). The aggregate score was then used to classify variants as pathogenic; likely pathogenic; VUS; likely benign; or benign. Factors considered included variant type and location within the gene; functional studies; cosegregation within families; previous publication in peer-reviewed literature; documentation in ClinVar, 11 the public access archive of phenotype-genotype relationships or in disease/ gene-specific databases where available 12, 13 ; general population variant frequencies, identified through the Exome Aggregation Consortium, 14 a public access database of genetic variation in 60 706 unrelated individuals; and in silico pathogenicity prediction, performed using the Complementary Annotation Dependent Depletion algorithm. 15 Public access databases were interrogated in September 2016.
Statistical Analysis
Statistical analysis was performed using SPSS version 22.0 (Institutional Software, SPSS, Armonk, NY). Continuous variables were compared by using the 2-tailed Student's t test or analysis of variance when comparing ≥3 groups. Categorical variables were compared using the χ 2 test. P values <0.05 were considered significant. Continuous variables are expressed as mean±SD. A logistic regression model was used to identify independent associations with a positive genetic test. Variables were inspected for any significant interactions. Available clinical variables were initially incorporated with backwards elimination used to identify the best fit. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Clinical Characteristics
Of 375 cardiac arrest survivors in CASPER, genetic testing was undertaken in 175 (mean age 39±15 years, 56% male). One case was excluded because the genetic report was incomplete and could not be verified, giving a cohort of 174. Patients who underwent genetic testing were younger than those who did not and were less likely to have a clinical phenotype (see Data Supplement). A pathogenic variant (1 homozygous) was identified in 29 (17%) individuals. One or more VUS were identified in 32 (18%) patients. There were 70 VUS identified in total (2.2 VUS/patient; range 1-9). Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9.7) and a family history of sudden death (odds ratio, 3.2; 95% confidence interval, 1.1-9.4) were independent predictors of a pathogenic variant. Identification of a clinical phenotype was associated with a higher yield on univariate analysis (P=0.01) but not when corrected for prior syncope and family history of sudden death (odds ratio, 2.3; 95% confidence interval, 0.9-5.5). Clinical characteristics are shown in Table 1 .
There were 27 unique pathogenic variants identified in 15 genes (see Table 2 ). Three unrelated individuals had the same variant in CACNA1C (c.2570C>T, p.Pro857Leu). Pathogenic variants in genes associated with LQTS and arrhythmogenic RV cardiomyopathy were most commonly identified. Pathogenic variants in genes associated with cardiomyopathy were identified in 11 (38%) individuals.
Of these 11, five (45%) had no apparent clinical phenotype. The mean age of these patients was 31 years (range 14-44) and was similar to phenotype-negative cases with pathogenic variants in arrhythmia genes (P=0.75). One patient with a LMNA variant developed severe left ventricular systolic impairment 4 years after the cardiac arrest. One patient with a DSP variant had minor diagnostic criteria for arrhythmogenic RV cardiomyopathy. Imaging was normal in the remaining 3 (echocardiogram 2 and cardiac magnetic resonance imaging 1). Follow-up imaging 2 years postcardiac arrest remained normal in 1 patient, with a pathogenic nonsense variant in PLN (c.116T>G, p.Leu39Ter).
There were 70 unique VUS identified in 30 genes. A full list of all VUS is provided in the Data Supplement.
Role of Clinical Phenotype
A clinical phenotype was identified in 72 (41%) individuals. Pathogenic variants were identified in 18 (25%) of phenotypepositive patients, most commonly in those with an arrhythmogenic RV cardiomyopathy phenotype. The frequencies of pathogenic variants in the most common phenotypes are shown in Table 3 . VUS were identified in 13 (18%) of phenotype-positive individuals.
A pathogenic variant was identified in 11 (11%) phenotype-negative patients, with a higher yield in broad multiphenotype testing than other types of testing (21% versus 8%; P=0.04). The frequency of VUS identification also significantly increased with broad multiphenotype panels (55% versus 5%; P<0.01). The yields of different genetic testing strategies in phenotype-negative patients are shown in Figure 2 .
Variant Reclassification and Inter-Laboratory Comparison
The original laboratory reports identified 141 variants in 66 patients (29 pathogenic and 112 VUS). Fifty (35%) variants were reclassified after independent assessment VUS were reclassified as benign polymorphisms in 42 instances, largely based on high general population frequencies. The majority of VUS were identified in phenotypenegative individuals who underwent broad multiphenotype genetic testing. These panels were performed by 3 commercial laboratories in 88% of cases. The number of genes included in the next-generation sequencing panels was different for each laboratory, although the yield of pathogenic variants was similar. The number of VUS/patient and VUS/ genes tested/patient, as originally reported, also differed significantly (See Table 4 ).
Cascade Family Screening
Assessment of first-degree relatives of survivors with either genetic or clinical evaluation was performed in 11 of the 29 cases where a pathogenic/likely pathogenic variant was identified. Focused genetic testing was performed in 21 relatives from 9 families, with variants identified in 12 (57%). Details of the cascade screening are included in the Data Supplement.
Discussion The Yield of Genetic Testing
Genetic testing in this large heterogeneous cohort of unexplained cardiac arrest survivors revealed a pathogenic variant in 17% of cases. This illustrates the principle that genetic cardiac disease may first present with life-threatening arrhythmia even in the absence of an identifiable clinical phenotype. Therefore, genetic testing in unexplained cardiac arrest survivors may be considered. Future studies are required to fully assess the clinical utility, effect on patient management, and cost-effectiveness of such a strategy.
A family history of sudden death and a history of prior syncope were independently associated with a higher yield of pathogenic variants. This is understandable because a genetically mediated substrate is more likely to present with recurrent arrhythmic episodes and affect multiple family members. The presence of these features may be used to direct genetic testing to those groups where the yield is highest, especially in healthcare systems where resources may be limited.
Identification of a clinical phenotype may have also been expected to lead to a higher yield of pathogenic variants because it allows for directed genetic testing, while those with no identifiable clinical phenotype may have been expected to have negative testing; familial cases of idiopathic ventricular fibrillation are rare and, other than the Dutch founder mutation in DPP6, 16,17 genetic etiologies have not readily been identified.
However, while the presence of a clinical phenotype was associated with a higher yield on univariate analysis, it was of borderline significance when corrected for other significant clinical features. This may be explained by the limitations of phenotypic testing and the difficulties of making an accurate diagnosis based on mild phenotypic features. Only 20% of those with a definite or probable clinical diagnosis of LQTS had a pathogenic variant identified compared with 75% expected in usual practice. 3 Because all these patients had normal resting QTc measurements, as per the study inclusion criteria, diagnosis was largely based on provocative testing with exercise ECG or epinephrine infusion. It has previously been shown that epinephrine infusion in particular is a sensitive but not specific test for LQTS. 10 The borderline effect of clinical phenotype on yields of pathogenic variants may, therefore, be explained by physician bias toward sensitive rather than specific investigations in the setting of an unexplained cardiac arrest leading to overdiagnosis on clinical grounds.
The genetic testing strategy used also had an influence on the yield of both pathogenic variants and VUS. Focusing on phenotype-negative patients, where a commonly accepted strategy is not available, yields of pathogenic variants were higher when broad multiphenotype panels were used compared with other strategies. The use of broad panels (including ≤150 genes associated with arrhythmia syndromes or cardiomyopathies) identified pathogenic variants in 21% of phenotype-negative cases. Extrapolation of this yield to the 72 phenotype-negative cases where alternative testing strategies were used would have led to the identification of a pathogenic variant in an additional 9 cases. Given the limitations of phenotypic testing discussed earlier, it may be possible that the yield in the phenotype-positive group would also have been increased if such a hypothesis-free strategy was undertaken. Interestingly, recent molecular autopsy studies using similarly large gene panels in the investigation of sudden arrhythmic death syndrome, which can be thought of as analogous to unexplained cardiac arrest, have reported comparable yields: Nunn et al 18 reported a yield of 29% using a 135 gene panel in 59 sudden arrhythmic death syndrome victims, and more recently, Bagnall et al 5 reported a 26% yield testing 46 genes in 113 unexplained sudden cardiac deaths.
Broad multiphenotype panels also identified ≥1 VUS in 55% of cases with ≤7 VUS in a single patient. The VUS is currently the biggest challenge in clinical cardiogenetics, and freeing patients and physicians from genetic purgatory 19 requires significant time, resources, and expertise. We, therefore, conclude that broad-panel testing should be undertaken only in dedicated clinics with the appropriate infrastructure and expertise to not only interpret and act on pathogenic variants, but also to critically appraise the nearly inevitable VUS when testing is performed. Such reappraisal of variants must also be serially repeated because their significance may change over time: 35% of variants originally reported were subsequently reclassified when reassessed. Time since the original report for reclassified variants was 3.4±2.2 years and was similar for variants whose classification did not change (P=0.45). Furthermore, similar to recent studies, 20 we observed significant variation between laboratories regarding variant ascertainment, perhaps reflecting contrasting philosophies with respect to the balance between sensitivity and specificity of findings, meaning an uninformed clinician is not able to always simply rely on the interpretation of the reporting laboratory. It is hoped that with increasing sizes of control populations, greater understanding of the functional implications of identified variants, and evolving guidelines for variant classification, 21 less heterogeneity will be seen between laboratories and that the proportion of VUS will decrease in the future. VUS were frequently identified in minor arrhythmia genes where substantial evidence connecting them to sudden death is limited or absent. Subsequently, the signal/noise ratio for these genes is low. It may be that omitting such genes from future sudden death panels may also reduce numbers of VUS without significantly reducing rates of pathogenic variant identification.
Genes Implicated in Unexplained Cardiac Arrest
The majority of genes in which pathogenic variants were identified have been well described in association with LQTS, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Several minor LQTS genes (representing LQTS4-12) were also implicated. Of note, a single variant in CACNA1C (c.2570C>T, p.Pro857Leu) was identified in 3 unrelated individuals. Two had a clinical phenotype of LQTS, while the third had minor findings insufficient for a clinical diagnosis. This variant was first reported in 2013 in association with autosomal dominant LQTS 22 with a history of sudden death in the affected family. CACNA1C encodes the α-subunit of the L-type calcium channel (Cav 1.2). 23 The variant localizes to a key proline, P, glutamic acid, E, serine, S, and threonine, T domain in which several other pathogenic variants have been identified. proline, P, glutamic acid, E, serine, S, and threonine, T domains act to signal protein degradation. 24 Functional studies of other pathogenic variants within the same domain (eg, Pro857Arg) have shown an increased I Ca,L current density because of increased channel stability at the cell membrane. Further investigation is required to ascertain whether this particular variant is associated with an increased risk of sudden death.
Cardiomyopathy genes were also implicated in phenotype-negative patients. This is again in keeping with the recent molecular autopsy study by Bagnall et al, 5 in which a significant proportion of pathogenic variants identified in cases with structurally normal hearts at postmortem were in cardiomyopathy-associated genes. The notion that pathogenic variants in cardiomyopathy genes may result in sudden death without manifest structural change both prompts a reassessment of the accepted mechanisms of arrhythmia in such cases and supports a humble approach to investigation of sudden death, where the limitations of phenotyping are recognized and genetic testing is undertaken with an open mind, as discussed earlier. No clinical features were identified as predicting pathogenic variants in cardiomyopathy genes in phenotype-negative cases, although the small numbers prevent detailed analysis.
Because of the retrospective nature of this study, it is possible that referral bias may have led to an overestimate of the incidence of pathogenic variants in unexplained cardiac arrest. Large-scale prospective investigation with systematic broadpanel genetic testing is necessary to identify the true incidence, which may then inform whether such a strategy should be recommended for all unexplained cardiac arrest survivors. As stated earlier, the apparent high rate of VUS should certainly limit current testing to experienced centers, which may be focused on those with prior syncope or a family history of sudden death.
Study Limitations
Although the cohort is large, genetic testing was not systematic and was limited by available resources and contemporary technologies in some cases. Data regarding segregation of variants within families of cardiac arrest survivors is currently unavailable; at present, there are insufficient first-degree relatives enrolled in the registry to perform any meaningful analysis. This will be developed in the future. Because of the retrospective nature of the study, referral bias cannot be excluded.
Conclusion
Genetic testing identifies a pathogenic variant in a significant proportion of unexplained cardiac arrest even in the absence of an identifiable clinical phenotype. Prior syncope and a family history of sudden death are predictors of a higher yield of pathogenic variants. Broad multiphenotype panels have the highest yield in phenotype-negative cases but frequently identify VUS. Genetic testing may, therefore, be considered in unexplained cardiac arrest, but should be limited to specialist clinics with genetic interpretation expertise. Implicated genes include those associated with cardiomyopathy even in the absence of a clinical phenotype.
